Literature DB >> 27321440

Molecular epidemiology of HIV-1 infection in Europe: An overview.

Apostolos Beloukas1, Alexandros Psarris2, Polina Giannelou2, Evangelia Kostaki2, Angelos Hatzakis2, Dimitrios Paraskevis3.   

Abstract

Human Immunodeficiency Virus type 1 (HIV-1) is characterised by vast genetic diversity. Globally circulating HIV-1 viruses are classified into distinct phylogenetic strains (subtypes, sub-subtypes) and several recombinant forms. Here we describe the characteristics and evolution of European HIV-1 epidemic over time through a review of published literature and updated queries of existing HIV-1 sequence databases. HIV-1 in Western and Central Europe was introduced in the early-1980s in the form of subtype B, which is still the predominant clade. However, in Eastern Europe (Former Soviet Union (FSU) countries and Russia) the predominant strain, introduced into Ukraine in the mid-1990s, is subtype A (AFSU) with transmission mostly occurring in People Who Inject Drugs (PWID). In recent years, the epidemic is evolving towards a complex tapestry with an increase in the prevalence of non-B subtypes and recombinants in Western and Central Europe. Non-B epidemics are mainly associated with immigrants, heterosexuals and females but more recently, non-B clades have also spread amongst groups where non-B strains were previously absent - non-immigrant European populations and amongst men having sex with men (MSM). In some countries, non-B clades have spread amongst the native population, for example subtype G in Portugal and subtype A in Greece, Albania and Cyprus. Romania provides a unique case where sub-subtype F1 has predominated throughout the epidemic. In contrast, HIV-1 epidemic in FSU countries remains more homogeneous with AFSU clade predominating in all countries. The differences between the evolution of the Western epidemic and the Eastern epidemic may be attributable to differences in transmission risk behaviours, lifestyle and the patterns of human mobility. The study of HIV-1 epidemic diversity provides a useful tool by which we can understand the history of the pandemic in addition to allowing us to monitor the spread and growth of the epidemic over time. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  European HIV-1 epidemic; Genetic diversity; HIV-1; Molecular epidemiology; Phylogeny; Subtypes

Mesh:

Year:  2016        PMID: 27321440     DOI: 10.1016/j.meegid.2016.06.033

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  23 in total

1.  Reconstruction of the Genetic History and the Current Spread of HIV-1 Subtype A in Germany.

Authors:  Kirsten Hanke; Nuno Rodrigues Faria; Denise Kühnert; Kaveh Pouran Yousef; Andrea Hauser; Karolin Meixenberger; Alexandra Hofmann; Viviane Bremer; Barbara Bartmeyer; Oliver Pybus; Claudia Kücherer; Max von Kleist; Norbert Bannert
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  Country Level Diversity of the HIV-1 Pandemic between 1990 and 2015.

Authors:  Joris Hemelaar; Shanghavie Loganathan; Ramyiadarsini Elangovan; Jason Yun; Leslie Dickson-Tetteh; Shona Kirtley
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

Review 3.  Back to basics in COVID-19: Antigens and antibodies-Completing the puzzle.

Authors:  Monica Neagu; Daniela Calina; Anca Oana Docea; Carolina Constantin; Tommaso Filippini; Marco Vinceti; Nikolaos Drakoulis; Konstantinos Poulas; Taxiarchis Konstantinos Nikolouzakis; Demetrios A Spandidos; Aristidis Tsatsakis
Journal:  J Cell Mol Med       Date:  2021-03-18       Impact factor: 5.310

Review 4.  Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings.

Authors:  Bluma G Brenner; Ruxandra-Ilinca Ibanescu; Isabelle Hardy; Michel Roger
Journal:  Viruses       Date:  2017-12-28       Impact factor: 5.048

5.  The molecular epidemiology of HIV-1 in the Comunidad Valenciana (Spain): analysis of transmission clusters.

Authors:  Juan Ángel Patiño-Galindo; Manoli Torres-Puente; María Alma Bracho; Ignacio Alastrué; Amparo Juan; David Navarro; María José Galindo; Dolores Ocete; Enrique Ortega; Concepción Gimeno; Josefina Belda; Victoria Domínguez; Rosario Moreno; Fernando González-Candelas
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

6.  Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.

Authors:  Andrea Hauser; Alexandra Hofmann; Karolin Meixenberger; Britta Altmann; Kirsten Hanke; Viviane Bremer; Barbara Bartmeyer; Norbert Bannert
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

7.  Multiple introductions and onward transmission of non-pandemic HIV-1 subtype B strains in North America and Europe.

Authors:  Marina Cabello; Hector Romero; Gonzalo Bello
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

8.  A high HIV-1 strain variability in London, UK, revealed by full-genome analysis: Results from the ICONIC project.

Authors:  Gonzalo Yebra; Dan Frampton; Tiziano Gallo Cassarino; Jade Raffle; Jonathan Hubb; R Bridget Ferns; Laura Waters; C Y William Tong; Zisis Kozlakidis; Andrew Hayward; Paul Kellam; Deenan Pillay; Duncan Clark; Eleni Nastouli; Andrew J Leigh Brown
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

9.  Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North Africa.

Authors:  Malik Sallam; Gülşen Özkaya Şahin; Mikael Ingman; Anders Widell; Joakim Esbjörnsson; Patrik Medstrand
Journal:  Heliyon       Date:  2017-07-10

10.  HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011-2016 update.

Authors:  Maja M Lunar; Snježana Židovec Lepej; Janez Tomažič; Tomaž D Vovko; Blaž Pečavar; Gabriele Turel; Manja Maver; Mario Poljak
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.